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Psoriasis is a chronic skin disorder of unsolved
pathogenesis affecting skin in 2–3% of the general
population. Research into the pathogenesis of
psoriasis has profited from suitable animal models.
Previously, we reported on the CD18 hypomorphic
(CD18hypo) PL/J mouse model clinically resembling
human psoriasis, which is characterized by reduced
expression of the common chain of b2-integrins
(CD11/CD18) to only 2–16% of wild-type levels. Aside
from common clinical and pathophysiological fea-
tures shared with human psoriasis, the psoriasiform
skin disease in CD18hypo PL/J mice also depends on
the presence of CD4þ T-cells. This review focuses on
the role of activated macrophages in the pathogenesis
of CD18hypo T-cell-mediated mouse model of psoria-
sis, and extends our understanding in unrestrained
pathogenic T-cells whose activation may be crucial for
the recruitment and activation of macrophages within
skin. The findings in the CD18hypo PL/J model are
discussed in the context of current literatures of
human and other autoimmune disorders.
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doi:10.1038/jid.2009.43; published online 26 February 2009
INTRODUCTION
Skin from psoriatic patients is characterized by a dense
dermal infiltrate that predominantly consists of T-cells,
dendritic cells (DCs), natural killer T-cells, and macrophages
(Clark and Kupper, 2006). The epidermis of psoriatic skin is
hyperproliferative and fails to undergo normal differentiation,
resulting in a marked thickening of the epidermis and
increased scale formation. The dispute in the field is whether
psoriasis is a disease of autoreactive T-cells or whether it
reflects an intrinsic defect within the epidermis, or both.
There is more recent evidence from genetic mouse models
that macrophages can contribute to T-cell-mediated and
epidermis-mediated psoriasiform skin inflammation (Stratis
et al., 2006; Wang et al., 2006).
Activated macrophages are major producers of proinflam-
matory cytokines such as tumor necrosis factor-a (TNF-a), IL-
1b, and IL-6 (Salkowski et al., 1995; Marble et al., 2007), and
play a crucial role in modulating immune responses (Holt
et al., 1993; Thepen et al., 1994; Gordon, 1995). Macro-
phages are heterogeneous and versatile bone marrow-derived
cells that produce a wide range of mediators and exert a
multitude of biological functions (Ganz, 1993). They can not
only serve as antigen-presenting cells, but also directly inhibit
antigen presentation by DCs (Holt et al., 1993). T-cell
proliferation, phenotype, and ultimately the type of immune
response induced, can distinctly be influenced by macro-
phages (Thepen et al., 1994, 1996; Strickland et al., 1996;
Grewe et al., 1998). Macrophages are specifically polarized
by the microenvironment to mount different functional
programs. Initial signals from microbes, through their
pathogen-associated molecular patterns (Schnare et al.,
2000), followed by a second signal, such as IFN-g, gives rise
to ‘‘classically activated macrophages’’. In early immune
responses, IFN-g is produced by natural killer and natural
killer T-cells; later the main source of IFN-g are antigen-
specific T-helper-1 (Th1) cells (Young, 2006). These stimuli
generally activate macrophages to produce TNF-a, monocyte
chemotactic protein-1 (MCP-1), inducible nitric oxide
synthase (iNOS), IFN-g, and to promote strong IL-12-mediated
Th1 responses. When macrophages are activated in the
presence of IL-4, IL-10, transforming growth factor-b, or
glucocorticoids, they become ‘‘alternatively activated macro-
phages’’ being characterized by dectin-1 expression and
supporting Th2-associated immune responses. However,
activation of dectin-1 with the fungal b-glucan triggers a
severe autoimmune arthritis in genetically susceptible mice
(Yoshitomi et al., 2005). Thus, in inflammatory processes
macrophages contribute to both initiation of inflammation
and to its resolution. However, during chronic inflammatory
responses in the skin and most likely other tissues, interaction
between macrophages and T-cells may lead to a vicious
cycle, which, by itself, is capable of maintaining local
inflammation without the necessity of external stimuli (Avice
et al., 1998).
To characterize mouse macrophages in various biological
processes, a panel of antibody-defined markers, expressed
during different stages of mouse macrophage development,
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was previously reported. These markers included (1) macro-
phage precursors and immature macrophages (ER-MP12,
ER-MP20, ER-MP54, ER-MP58); (2) mature macrophages
in general (F4/80, BM8, Mac-1, Mac-2, ER-BMDM1); (3)
macrophage subsets (ER-HR3, ER-MP23, ER-TR9, Forssman
antigen, MOMA-1, MOMA-2, Monts-4, SER-4), and (4) IFN-
g-stimulated macrophages (H-2Ia, LFA-1, intercellular
adhesion molecule-1, 158.2, MBR-2, TM-2, TM-4, TM-5)
(Leenen et al., 1994).
In the past, some surface markers, including CD14, CD68,
HLA-DR, RM3/1, and CD11c, have been used to describe the
phenotypic diversity of the dermal macrophage population in
humans (Weber-Matthiesen and Sterry, 1990; Djemadji-
Oudjiel et al., 1996). Besides these markers, a recent study
reported that a population of dermal macrophage/macro-
phage-like cells expresses CD163 and factor XIIIa in normal
human skin (Nestle and Nickoloff, 2007; Zaba et al., 2007b).
CD163þ cells phagocytose large particles in a tattoo and
have the structural features of macrophages (Zaba et al.,
2007b). CD163 is a hemoglobin/haptoglobin complex-
binding macrophage scavenger receptor expressed on the
majority of tissue macrophages (Fabriek et al., 2005).
Expression of factor XIIIa is related to cell activation and is
inducible via IL-4 in alternatively activated macrophages
(Torocsik et al., 2005).
In human psoriasis, the number of epithelium-lining
macrophages was reported to increase in lesional skin. These
macrophages, which line dermal–epidermal junctions, may
play a role in the regulation of epidermal proliferation and
differentiation (van den Oord and de Wolf-Peeters, 1994;
Djemadji-Oudjiel et al., 1996) or vigorous interactions
between macrophages and keratinocytes (Djemadji-Oudjiel
et al., 1996), and may be involved in the pathogenesis of
psoriasis (van den Oord and de Wolf-Peeters, 1994;
Djemadji-Oudjiel et al., 1996). Macrophages secrete a
variety of proinflammatory cytokines, such as TNF-a, IL-1b,
IFN a/b, IL-6, IL-10, IL-12, and IL-18 cytokines, under
different conditions (Willment et al., 2003).
Research into the pathogenesis of human psoriasis has
profited, at least in part, from suitable animal models. Most of
these, however, reveal only a single or a few aspects
resembling human psoriasis (Carroll et al., 1995; Schon
et al., 1997; Pasparakis et al., 2002; Sano et al., 2005; Zenz
et al., 2005).
Previously, introduction of an insertion mutation in the
murine CD18 gene, resulting in duplication of exons 2 and 3,
yielded a mouse model with severe reduction of CD18
expression, with only 2–16% of wild-type (wt) levels (Wilson
et al., 1993). Due to this hypomorphic CD18 mutation
(CD18hypo), a chronic inflammatory skin disease develops in
PL/J mice, which closely resembles human psoriasis clini-
cally, histologically, in its polygenic nature and in its
response to therapy (Bullard et al., 1996; Kess et al., 2003;
Wang et al., 2006). Affected mice present with erythema,
crusts, and scaling, as well as abnormal keratinocyte
proliferation/differentiation, subcorneal microabscesses, and
increased inflammatory infiltrate. In severely affected mice,
reversible alopecia was observed, a feature, which may only
rarely, if at all, occur in human psoriasis (Shuster, 1972). The
psoriasiform skin disease was only observed when the
CD18hypo mutation was backcrossed on the PL/J, but not on
the C57BL/6J or 129/SvEv inbred mouse strains. Homozygous
mutant mice on a PL/JC57BL/6J F1 background did not
develop the disease, despite the CD18hypo mutation. Back-
cross analysis suggests that, in addition to the CD18hypo
mutation, a small number of other genes determine suscepti-
bility to the disease (Bullard et al., 1996; Kess et al., 2006).
Hence, the CD18hypo PL/J model qualifies as a polygenic
model for chronic skin inflammation. Such a polygenic
nature has been claimed for human psoriasis (Schon and
Boehncke, 2005).
As in patients treated for severe psoriasis (van de Kerkhof
and Weemaes, 1990; Feldman et al., 2001), this chronic
psoriasiform skin disease of the CD18hypo PL/J mouse model
can be suppressed by corticosteroids (dexamethasone),
suggesting involvement of an inflammatory process. T-cells
are important in the generation of the inflammatory skin
disease in this CD18hypo PL/J model (Kess et al., 2003; Barlow
et al., 2004). This is analogous to the affected skin of psoriatic
patients in which CD4þ T-cells prevail (Morel et al., 1992;
Wrone-Smith and Nickoloff, 1996; Schon et al., 1997;
Sugiyama et al., 2005; Conrad et al., 2007).
CD18 represents the common b2-chain of the b2-integrin
family. b2-Integrins (CD11/CD18) are leukocyte adhesion
molecules exclusively expressed on hemopoietic cells and
are responsible for cell–cell contacts in a variety of
inflammatory interactions (Hynes, 1987). At present, four
different b2-integrins have been characterized, all of which
are heterodimeric cell-surface molecules consisting of the
CD18 molecule and one of the CD11 molecules: CD11a,
CD11b, CD11c, or CD11d. These heterodimeric molecules
interact with more than 20 known ligands, of which the most
prominent belong to the intercellular adhesion molecule
family (Carlos and Harlan, 1994).
The pathogenic role of b2-integrins in human psoriasis and
other inflammatory skin diseases is less well understood.
Circumstantial evidence indicating that reduced CD18
expression may causally be involved in the development of
this psoriasiform dermatitis, comes from the clinical observa-
tion that some patients suffering from leukocyte adhesion
deficiency syndrome-1, with only moderately reduced CD18
expression levels, develop a psoriasiform skin disease
(van Pelt et al., 1998). Linkage analysis of psoriasis families
has identified a region on chromosome-17, including
among other loci the intercellular adhesion molecule-2
locus, an important ligand of the CD11/CD18 heterodimers
(Tomfohrde et al., 1994). Furthermore, polymorphisms in the
CD18 gene have been found that predispose to autoimmune
diseases (Gencik et al., 2000; Meller et al., 2001).
Until today, the cause of psoriasis remains unknown.
Here, we describe the causal contribution of activated
macrophages in the initiation and maintenance of the
psoriasiform skin disease, and summarize recent data on
the impaired function of regulatory T-cells (Treg-cells) being
responsible for the accelerated proliferation of pathogenic
T-cells, which contribute to the recruitment and activation of
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macrophages in CD18hypo mouse model of psoriasis. Under-
standing the role of activated macrophages in the pathogen-
esis of psoriasiform skin disease in CD18hypo PL/J mouse
model will help to develop new approaches for design of
therapeutics in chronic inflammatory skin diseases, such as
human psoriasis and other inflammatory diseases.
Macrophage infiltration is a hallmark in the inflamed skin
of CD18hypo PL/J mice
Subsets of both human and mouse monocytes can develop
into macrophages in various disease states (Grage-Griebenow
et al., 2001; Sunderkotter et al., 2004). A subset of monocytes
patrols tissues through long-range crawling on the resting
endothelium (Auffray et al., 2007). This patrolling behavior
was required for rapid tissue invasion at the site of an infection
by this ‘‘resident’’ monocyte population, which initiated an
early immune response and differentiated into tissue ‘‘resi-
dent’’ macrophages (Auffray et al., 2007). In peripheral
inflammation, Ly-6Cmed/high monocytes are recruited to the
affected sites to become inflammatory exudate macrophages
(Sunderkotter et al., 2004). Interestingly, monocytes are
abundant in the lesions of T-cell-mediated diseases (Iwahashi
et al., 2004; Schlitt et al., 2004). These findings suggest that
tissue macrophages derived from patrolling monocytes may
contribute to the pathogenesis of autoimmune diseases and
may represent a target for treatment.
Psoriasis is regarded as a T-cell-mediated disease (Schon
et al., 1997; Nickoloff and Wrone-Smith, 1999; Boyman
et al., 2004; Conrad et al., 2007). However, there is an
increasing body of correlative evidence that macrophages
may also be relevant for its pathophysiology (Gillitzer et al.,
1993; Nickoloff, 2000; Boyman et al., 2004; Marble et al.,
2007). Macrophages lining the epidermal–dermal junction
have repetitively been described in human psoriasis (Gillitzer
et al., 1993; van den Oord and de Wolf-Peeters, 1994;
Djemadji-Oudjiel et al., 1996; Nickoloff and Wrone-Smith,
1999; Marble et al., 2007).
As in psoriasis, activated macrophages were found to play
major roles in other T-cell-mediated autoimmune diseases
such as rheumatoid arthritis (Huang et al., 2007), multiple
sclerosis (Greter et al., 2005), and the experimental auto-
immune encephalitis (Drew et al., 2005), or in type-I diabetes
in the non-obese diabetic mouse model (Rosmalen et al.,
2000).
In this review, we will focus on the role of macrophages in
CD18hypo PL/J mouse model for psoriasis and other T-cell-
mediated diseases (Jun et al., 1999; Wang et al., 2006).
To define the contribution of macrophages, we investi-
gated the composition of the inflammatory cellular infiltrate
in the psoriasiform skin of the CD18hypo mice and the
respective skin draining lymph nodes (DLNs). Immunohisto-
logical analysis of skin sections taken from affected CD18hypo
and CD18wt mice showed remarkably increased number of
F4/80þ macrophages in diseased skin of CD18hypo PL/J mice
compared with skin of CD18wt animals. In skin DLNs, an
increased number of MOMA-2þ monocyte/macrophages,
which had apparently entered via the medullar
and subcapsular sinuses, were detected in histology and
confirmed by FACS analysis (Figure 1). Interestingly, similar
as in human psoriasis, these macrophages belong to the
classical activation type, as they strongly stained for iNOS
and TNF-a, as well as of the alternative activation type, as
they expressed dectin-1 on their surface. Our finding is of
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Figure 1. Increase in macrophages numbers in lesional skin and skin DLNs of
affected CD18hypo mice. Skin cryosections from CD18wt (a) and affected
CD18hypo mice (b) were stained with F4/80-Alexa-488 for detecting
infiltrating macrophages (green) into the skin. Cell nuclei (blue) were
counterstained with 40,6-diamidino-2-phenylindole (original magnification
40; inset original magnification  100). e, epidermis; d, dermis; h, hair
follicle. The dotted lines indicate the border between the epidermis and
dermis. (c) To quantify macrophages in the skin of affected CD18hypo and
CD18wt mice, the positively stained cells were calculated. For all
measurements, the median of macrophages counted in 12 high-power fields
(HPFs) (n¼4) is presented (**Po0.0001 by Student’s t-test). Immunostaining
with macrophage/monocyte–FITC (clone MOMA-2) was performed on
cryosections of skin DLNs from CD18wt (d) and affected CD18hypo mice (e).
Infiltrated macrophages (green) were found in the medullar and subcapsular
sinuses, as indicated by arrows. Cell nuclei (red) were counterstained with
propidium iodide (original magnification 20). To quantify macrophages in
the skin DLNs of CD18wt (f) and affected CD18hypo mice (g), skin DLNs cells
were labeled with MOMA-2–FITC mAb and analyzed by flow cytometry.
Dotted line, isotype control; solid histogram, MOMA-2 staining. (h) Total
number of macrophages in skin DLNs of CD18hypo and CD18wt mice (n¼ 6).
One representative experiment out of three is shown (**Po0.01 by Student’s
t-test). (This figure was reproduced from Wang et al. (2006), with permission
from the American Society for Clinical Investigation).
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particular interest as the infiltrating macrophages in the
murine psoriasis model were similarly described for human
psoriasis (Nickoloff, 2000; Marble et al., 2007). The
pathogenic involvement of these sub-epidermally located
macrophages designated as ‘‘epithelium lining macro-
phages’’ is largely unknown in human psoriasis (Gillitzer
et al., 1993; van den Oord and de Wolf-Peeters, 1994;
Djemadji-Oudjiel et al., 1996; Boyman et al., 2004;
Vestergaard et al., 2004). Here, we show that the number
of macrophages was greatly increased in the lesional skin of
the chronic inflammatory skin disease in CD18hypo mice
corresponding to human psoriasis. Therefore, the CD18hypo
PL/J mouse model is a valuable tool to study the potential role
of macrophages in the pathogenesis psoriasis.
Macrophages represent an important source of TNF-a in
lesional skin of CD18hypo PL/J mice
TNF-a is a multifunctional cytokine that mediates inflamma-
tion, immune response, and apoptosis (Locksley et al., 2001).
Inappropriate production or persistent activation of TNF-a
participates in a wide spectrum of diseases, including septic
shock, diabetes, cancer, graft rejection, rheumatoid arthritis,
and Crohn’s disease (Banno et al., 2004). Accumulating
evidence indicates that TNF-a also has a significant role in
normal development and homeostasis of several organs. Mice
deficient in TNF-a lack germinal center and show increased
susceptibility to microbial pathogens due to incomplete
inflammatory responses (Pasparakis et al., 1996). TNF
receptor-1 (TNFR1)-mutant mice show similar abnormalities,
in addition to defective formation of Peyer’s patches (Fu
and Chaplin, 1999). In skin, TNF-a is the master cytokine
promoting inflammatory diseases, such as psoriasis, contact
dermatitis, drug eruptions, cutaneous T-cell lymphoma, and
others (Teraki et al., 1994). The concentration of TNF-a is
distinctly increased in skin after injury (Kock et al., 1990) and
is essential for angiogenesis during wound healing (Leibovich
et al., 1987). There is evidence that the levels of TNF-a
receptors are highly upregulated in the involved skin areas of
psoriatic patients (Kristensen et al., 1993), and that the
biological activity of TNF-a is elevated in psoriatic skin
lesions (Ettehadi et al., 1994).
TNF-a is biologically active as trimer (Pfeffer, 2003). It is
produced primarily by activated macrophages and other cell
types, including epidermal keratinocytes (Chen and Goeddel,
2002), DCs (Marble et al., 2007), and mast cells (Echtenacher
et al., 1996; Malaviya et al., 1996; Ackermann and Harvima,
1998). A low level of TNF-a is present in the upper layer of
the healthy epidermis, but its synthesis and release from
keratinocytes are greatly augmented by injury, infection, UV
irradiation, and contact allergy (Kock et al., 1990). Of the two
distinct cell-surface receptors for TNF-a, TNFR1, and TNFR2,
keratinocytes mainly express TNFR1 (Banno et al., 2004). The
binding of TNF-a to TNFR1 triggers a series of intracellular
events resulting in activation of transcription factors, includ-
ing nuclear factor-kB, activator protein-1, CCAAT enhancer-
binding protein b, and others (Baud and Karin, 2001), which
are responsible for induction of genes important for diverse
biological processes, including cell growth and death, and
immune, inflammatory, and stress responses (Chen and
Goeddel, 2002). TNF-a activates the immune responses
through induction of signals, such as IL-1 and IL-8,
transforming growth factor-b, intercellular adhesion mole-
cule-1, and so on (Banno et al., 2004).
To study the cellular sources of TNF-a in the lesional skin
of affected CD18hypo mice, double immunofluorescence
stainings performed on cryosections derived from lesional
skin of CD18hypo mice and healthy skin from CD18wt mice
revealed that CD117þ mast cells, CD31þ endothelial cells,
and especially F4/80þ macrophages were important sources
of TNF-a (Figure 2). This correlates with the finding that
macrophages are important source of TNF-a in psoriatic
lesions derived from patients (Marble et al., 2007).
The suggested cellular sources of TNF-a release in human
psoriasis include T-cells, mast cells, and endothelial cells
(Schlaak et al., 1994; Ackermann and Harvima, 1998).
Notably, in a recent paper CD68þ macrophages and
CD11cþ dermal DCs were identified as important TNF-a
source in human psoriasis and upon treatment with
adalimumab (anti-TNF-a antibody) macrophage levels de-
creased in the plaque psoriasis, with complete resolution of
clinical psoriasis (Marble et al., 2007). In line with this
finding (Marble et al., 2007), we also identified CD68þ
macrophages as important TNF-a source in human psoriatic
skin, which had distinctly decreased number and TNF-a
concentration following bath-PUVA therapy (our unpub-
lished data). This was also found in a T-cell-independent
mouse model, with an increase in TNF-a in macrophages
(Stratis et al., 2006). Additionally, a distinct population of
TNF-a and inducible nitric oxide synthase-expressing
CD11cþ DCs, resembling murine ‘‘TipDCs’’ (TNF-iNOS-
producing DCs), has been found to abundantly infiltrate
human psoriatic plaques and to be reduced after
treatment with efalizumab (anti CD11a) (Lowes et al.,
2005). As b2-integrins are virtually undetectable on macro-
phages derived from CD18hypo mice, these cells most likely
belong to the pool of detected classically activated macro-
phages.
The most abundantly studied macrophage phenotype is
the classically activated macrophage characterized by
production of TNF-a and iNOS. This macrophage subset
develops in response to proinflammatory stimuli such as Th1
cytokines or bacterial products (Aderem and Ulevitch, 2000).
Macrophages differentiating in the presence of Th2 cytokines
have been designated as alternatively activated macrophages.
This subset is characterized by enhanced expression of
dectin-1, eosinophil chemotactic factor (Ym1/ECF-L), and
arginase-1. These markers allow to distinguish them from
classically activated macrophages (Stein et al., 1992). The
infiltrating macrophages as found in the CD18hypo PL/J mouse
model reveal both classical and alternative activation
markers, as similarly described for human psoriasis (Nickol-
off, 2000). Interestingly, both classically activated macro-
phages, characterized by production of TNF-a and iNOS,
and alternatively activated macrophages, characterized by
enhanced dectin-1 and arginase-1 expression, are present in
the lesional skin of CD18hypo PL/J mice (Wang et al., 2006).
www.jidonline.org 1103
H Wang et al.
Role of Macrophages in the CD18 Hypomorphic Murine Model of Psoriasis
Blocking TNF-a by etanercept results in improvement
of the psoriasiform skin inflammation in CD18hypo PL/J mice
In the past 20 years it has become clear that epidermal
changes in psoriasis are secondary to robust immune
activation within psoriatic plaques characterized by in-
creased numbers and activation of both T lymphocytes and
DCs (professional antigen-presenting cells) (Gottlieb et al.,
1986; Wrone-Smith and Nickoloff, 1996; Schon et al., 1997;
Krueger, 2002; Conrad et al., 2007). Some animal models
demonstrate a distinct role for T-cell activation, local
cutaneous T-cells, and TNF-a (Wrone-Smith and Nickoloff,
1996; Boyman et al., 2004). Clinically, agents that specifi-
cally block T-cells or TNF-a clear human psoriasis (Chaud-
hari et al., 2001; Gottlieb et al., 2003a, c; Gottlieb, 2004;
Gordon et al., 2005). TNF-a blocking induced by either
etanercept, a form of soluble p75 TNF-a receptor that binds
both TNF-a and lymphotoxin (LT) (Gottlieb, 2004), or
infliximab, a chimeric, monoclonal anti-TNF-a antibody
(Gottlieb et al., 2003b), or adalimumab, a fully human-
derived recombinant monoclonal antibody against TNF-a
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Figure 2. Activated macrophages are an important source of TNF-a. To investigate the cellular origin of TNF-a in lesional skin infiltrate, skin samples
from CD18wt and affected CD18hypo mice were double stained with anti-mouse TNF-a–FITC (green) or TNF-a-phycoerythrin (red), together with the
cell-specific markers CD117–Cy3 anti-mouse for mast cells (red) (a, b), CD31-Alexa-488 for endothelial cells (green) (d, e), keratin-14-Alexa-488 for
keratinocytes (green) (g, h), and F4/80-Alexa-488 for macrophages (green) (j, k). The overlay (yellow) represents TNF-a-producing cells. Cell nuclei were
counterstained with 40,6-diamidino-2-phenylindole (blue) (original magnification  20). e, epidermis; d, dermis; h, hair follicle. Dotted lines indicate the border
between epidermis and dermis. Quantitative analysis of the TNF-a-producing cells was performed by counting the cells staining positively for both TNF-a and
one of the cell markers CD117–Cy3 for mast cells (c), CD31 for endothelial cells (f), keratin-14 for keratinocytes (i), and F4/80 for macrophages (l) (yellow dots)
in the lesional skin of CD18hypo mice as compared with in CD18wt mice. Data are presented as median of positive counts in 12 high-power fields
(n¼12) (**Po0.01 by Student’s t-test). (This figure was reproduced from Wang et al. (2006), with permission from the American Society for Clinical Investigation).
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(Chew et al., 2004), results in improvement or resolution of
psoriasis. Clinical remission is associated with substantially
decreased numbers of intraepidermal T-cells and normal-
ization of epidermal proliferation and differentiation, as
measured by decreased epidermal thickness and normalized
protein expression of keratin-16 (Gottlieb et al., 2003a).
TNF-a, LT-a, and LT-b are NF-kB-regulated key mediators of
inflammation (Aggarwal, 2003). A recent publication shows
both TNF and LTs signaling being required for development
of the skin phenotype in the IKBa deficiency mouse model of
psoriasis (Rebholz et al., 2007). It is not known whether
resolution of psoriasis induced by TNF-a/LT blockade is due
to effects on T-cells, DCs, macrophages, or a combination of
these. So far it is shown that in humans TNF blockade by
etanercept induces early inhibitory effects on IL-23 release
from DCs, which is known to drive Th17-cell proliferation, as
well as having direct effects on Th17 products (IL17, IL22,
CCL20) and late inhibitory effects on Th1 effectors such as
IFN-g (Zaba et al., 2007a). Notably, levels of TipDCs, a new
type of inflammatory myeloid CD11cþ DCs described
recently in psoriasis (Lee et al., 2004), were significantly
reduced in the lesional skin of psoriatic patients with
etanercept treatment (Zaba et al., 2007a). TipDCs produce
multiple inflammatory products, including iNOS, TNF-a,
IL-20, and IL-23, in psoriatic lesions (Zaba et al., 2007a).
Among them, IL-23 released by TipDCs is supposed to
directly drive Th17-cell proliferation (Zaba et al., 2007a). It is
of interest to identify whether TNF-a-producing macrophages
in CD18hypo PL/J mouse model of psoriasis share phenotypic
and functional features with TipDCs in human psoriasis.
Anti-TNF-a treatment was shown to resolve inflammation
in a number of autoimmune diseases such as experimental
autoimmune encephalomyelitis (Schilling et al., 2006), auto-
immune diabetes in non-obese diabetic mice (Wu et al.,
2002), collagen-induced arthritis (Willment et al., 2003), or
chronic ulcerative colitis (Popivanova et al., 2008; Table 1).
Etanercept is an ideal agent to study an effect of TNF-a
inhibition on cellular immune regulation in plaques, because
its actions are thought to be due to neutralization of TNF-a
and not due to depletion of cells bearing cell-surface TNF-a.
Following the observation that macrophages are a major
source for TNF-a, its causal relevance in the formation of the
psoriasiform skin disease in the CD18hypo PL/J mouse model
for psoriasis was analyzed. TNF-a was neutralized by
administrating etanercept once a day at a dose of 100mg
per mouse. To evaluate the severity of the psoriasiform
phenotype, an adapted psoriasis activity and severity index
(PASI) score was used for affected CD18hypo PL/J mice before
and after treatment with etanercept or the control (Kess et al.,
2003). Neutralization of TNF-a by etanercept significantly
decreased the adapted PASI score after 30 days of treatment
and significantly decreased the number of macrophages in
affected skin and skin DLNs. In contrast, no significant
improvement was observed in the mice treated with 0.9%
NaCl (control) (Figure 3).
Our data provide evidence for a mechanistic basis, with
activated TNF-a-releasing macrophages playing an essential
role in chronic psoriasiform skin disease. In fact, this view
was confirmed by the recent finding that macrophages and
DCs constitute a major source of TNF-a in human psoriasis
(Marble et al., 2007). This provides the basis for under-
standing the successful therapy of human psoriasis with a
variety of TNF-a-inhibitory agents. The next generation of
small molecules targeting different steps of TNF-a signaling
has been developed, some of which are currently being
tested in clinical trials (Palladino et al., 2003; Mease et al.,
2005; Weinberg et al., 2005; Cordoro and Feldman, 2007).
Mechanism of macrophage ‘suicide’ using clodronate
(CL2MDP) liposomes
As macrophages represent a major, but not the only, source
of TNF-a, use of TNF-a inhibitors with subsequent resolution
of psoriasis provides only circumstantial evidence that
macrophages play a major role in human psoriasis.
To gain more insight into the role of macrophages in
various models of inflammation, several approaches have
been used to reduce macrophage activity, including blockade
of secreted cytokines (Elliott et al., 1994), downregulation
of macrophage activity (van Roon et al., 2005) using Ricin
A-coupled antibodies directed against the high-affinity IgG
receptor, CD64 (Thepen et al., 2000), or liposomes contain-
ing dichloromethylene diphosphonate (clodronate liposomes)
(Van Rooijen et al., 1990; Kurimoto et al., 1994; Figure 4).
Previously, macrophage depletion with clodronate liposomes
proved to be effective in several animal models of diseases
where activated macrophages were involved in the patho-
genic mechanism, such as autoimmune diabetes in non-
obese diabetic mice (Nikolic et al., 2005), experimental
allergic encephalomyelitis (Polfliet et al., 2002; Greter et al.,
2005), serum-induced arthritis Solomon et al., 2005),
collagen-induced arthritis (Van Lent et al., 1998), or experi-
mental autoimmune anemia (Jordan et al., 2004; Table 1).
Clodronate liposomes have been shown to efficiently and
selectively deplete phagocytic macrophages by apoptosis
from spleen, liver, lymph nodes, and skin, whereas other
non-phagocytic immunocompetent cells, such as T-cells, B
cells, and mature DCs, are not eliminated (Van Rooijen et al.,
1990; Stratis et al., 2006; Wang et al., 2006). Additionally,
intradermal injections of clodronate liposomes did not
deplete mature Langerhans cells from the epidermis (Kur-
imoto et al., 1994). The large liposomes (40.8 mm) used in
our study were selectively phagocytosed by macrophages.
After injection of clodronate liposomes into the lesional skin,
skin macrophages phagocytosed clodronate liposomes and
the phospholipids bilayers of the liposomes were disrupted by
lysosomal phospholipase. Clodronate was then released intra-
cellularly, and drove macrophages into apoptosis (Figure 4).
Improvement of the psoriasiform skin inflammation after
depletion of skin macrophages in CD18hypo PL/J mice and
T-cell independent epidermal inhibitor of nuclear factor-jB
kinase 2-deficient mice
To analyze whether activated macrophages are mandatory in
the pathogenesis of the psoriasiform skin inflammation in
CD18hypo PL/J mice, macrophages were eliminated from the
skin of affected CD18hypo mice using clodronate liposomes.
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Depletion of macrophages in CD18hypo PL/J mice with a
severe inflammatory phenotype led to remarkable improve-
ment of the psoriasiform skin inflammation after 6 weeks of
treatment (Figure 5). The reduction in severity and extent of
erythema, plaque formation, and scaling after treatment with
clodronate liposomes was highly significant (7.67±1.03
versus 2.33±0.52, P¼0.0022) (Figure 5). In contrast, no
significant changes in PASI score were observed in four mice
treated with control liposomes (P¼0.3429) (Figure 5). Inter-
estingly, macrophages also play a pathogenic role in a T-cell-
independent, epidermis-based psoriasis murine model (Stratis
et al., 2006). This model was generated by deletion of
inhibitor of nuclear factor-kB kinase 2, specifically in the
epidermis. Notably, also in this model, macrophage levels
are increased at the interface between the epidermis and
dermis, and upon treatment with clodronate liposomes or
etanercept (anti-TNF-a), the skin inflammation resolved
(Stratis et al., 2006). These interesting data derived from
Table 1. The role of activated macrophages in mouse models of psoriasis and other autoimmune diseases
Model
Macrophages in the
inflammatory infiltrate
Disease resolution after
macrophage depletion
Disease
resolution after
anti-TNF-a
treatment Reference
Mouse models of psoriasis
CD18hypo PL/J Yes Yes Yes Wang et al. (2006)
Targeted IKK2 Yes Yes Yes Stratis et al. (2006)
Inducible epidermal deletion of
JunB
Yes Not reported Not reported Zenz et al. (2005)
IL-Ira KO Yes Not reported Not reported —
K5-latent TGF-b1 Yes Not reported Not reported —
Flacky skin (fsn/fsn) Yes Not reported Not reported —
Xenograft prepsoriatic skin
on AGR129
No Not reported Yes Boyman et al. (2004)
Involucrin–MEKl Yes Not reported Not reported —
K14–VEGF Yes Not reported Not reported —
Tie2 (Tek) Yes Not reported Not reported —
Integrin aE KO Yes Not reported Not reported Schon et al. (2000)
Xenograft prepsoriatic skin on
SCID
Yes Not reported Yes Wrone-Smith and Nickoloff
(1996)
Mouse models for autoimmune diseases
Experimental autoimmune
encephalomyelitis
Yes Yes Yes Schilling et al. (2006)
Autoimmune diabetes
(NOD mice)
Yes Yes Age-dependent
effects
Wu et al. (2002); Nikolic
et al. (2005)
Collagen-induced arthritis Yes Yes Yes Van Lent et al. (1998)
Chronic ulcerative colitis Yes Not reported Yes Popivanova et al. (2008)
Serum-induced arthritis Yes Yes Not reported Solomon et al. (2005)
Autoimmune hemolytic anemia Yes Yes Not reported Jordan et al. (2004)
IKK, inhibitor of nuclear factor-kB kinase; K14, keratin-14; K5, keratin-5; KO, knockout; NOD, non-obese diabetic; SCID, severe combined
immunodeficiency; TGF-b1, transforming growth factor-b1; TNF-a, tumor necrosis factor-a; VEGF, vascular endothelial growth factor.
Mouse models of psoriasis and other autoimmune diseases that were confirmed for presence of macrophages and TNF-a are listed.
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Figure 3. Reduction of the psoriasiform phenotype of affected CD18hypo
mice by administration of etanercept. Etanercept (100 mg per mouse)
was administrated intraperitoneally every day for a period of 30 days to
neutralize TNF-a. In parallel, injection of 0.9% NaCl was used as a control.
A significant difference in the adapted PASI score appears after treatment
with etanercept (a) (P¼ 0.0079 by Student’s t-test), but not after treatment
with 0.9% NaCl control (b) (P¼0.6514 by Student’s t-test). (This figure
was reproduced from Wang et al. (2006), with permission from the
American Society for Clinical Investigation.)
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two independent mouse models very much suggest that
macrophages play a central role in both epidermis-based and
T-cell-mediated pathways of inflammation. There is clinical
evidence that human psoriasis may not be a homogeneous
T-cell-mediated entity. In fact, some psoriatic patients treated
with biologics against T-cell emigration and/or activation do
not profit from this at all. This may support the view that the
therapeutic modulation of macrophage function contributes
to an alternate therapeutic strategy for psoriasis patients-
independent of whether their disease is mediated by T-cells
or not.
Apart from the success of directly targeting TNF-a in the
treatment of human psoriasis (Antoni and Manger, 2002;
Gordon et al., 2005), therapies that most likely impair
macrophage function by diminishing their production and
release of TNF-a, such as IL-4 (Ghoreschi et al., 2003), IL-11
(Trepicchio et al., 1999), and IL-12 (Kauffman et al., 2004),
have earlier been reported to improve this medical condition.
Recently, IL-20, which is produced by macrophages (Wolk
et al., 2002; Pestka et al., 2004), has been discovered to be
upregulated in psoriatic skin (Romer et al., 2003; Otkjaer
et al., 2005). It promotes hyperproliferation and abnormal
differentiation of keratinocytes both in vitro and in vivo
(Blumberg et al., 2001; Romer et al., 2003; Otkjaer et al.,
2005; Wolk et al., 2006). Furthermore, IL-20-transgenic
mice displayed skin abnormalities reminiscent of psoriasis
(Blumberg et al., 2001). It is suggested that IL-20 indirectly
exerts its proliferative effects on keratinocytes via immune
cells present in the psoriatic skin (reviewed by Stenderup
et al., 2007). Accumulating evidences indicate that IL-20 is
likely to be a target in psoriasis treatment. Thus, in addition to
other beneficial effects, these agents released by activated
macrophages may also exert their therapeutic efficacy by
silencing macrophages.
Most recently, a new drug-conjugated antibody (CD64–
calicheamicin (CD64-CaMi)) directed to the high-affinity
receptor for IgG (FcgRI) was shown to selectively eliminate
activated synovial macrophages in rheumatoid arthritis (van
Roon et al., 2005). Based On our findings, and that of others,
future studies may develop the potential therapeutic agents to
directly deplete activated macrophages for treatment of
autoimmune diseases such as psoriasis.
Macrophage
Apoptosis
Lysosome
LysosomeNucleus
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Figure 4. Mechanism of macrophage depletion using clodronate liposomes
in vivo. To selectively deplete macrophages in vivo, clodronate (CL2MDP)
liposomes have successfully been employed in a variety of experimental
systems. The mechanism of macrophage depletion using clodronate
liposomes is as follows. Macrophage ‘suicide’ liposomes, encapsulating the
clodronate molecules are ingested by macrophages via endocytosis. After
fusion with lysosomes containing phospholipases (arrowheads), the latter
disrupt the bilayers of the liposomes. The more concentric bilayers are
disrupted, the greater is the clodronate release into the cytoplasm of the cell.
The cells are then killed by clodronate through apoptosis. (This figure was
modified from http://www.clodronateliposomes.org.)
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Figure 5. Improvement of the psoriasiform phenotype of affected CD18hypo
mice by depletion of macrophages after local injection with clodronate
liposomes. Clodronate liposomes were injected subcutaneously at a dose of
50mg/200 ml weekly. Representative clinical picture of a CD18hypo mouse
with severe psoriasiform dermatitis before (a) and after 40 days of treatment
with clodronate liposomes (b). The severity of the psoriasiform phenotype as
assessed by the adapted PASI score was significantly reduced after clodronate
treatment (c), but not after treatment with control liposomes (d) (P¼0.3429
by Student’s t-test). (This figure was reproduced from Wang et al. (2006),
with permission from the American Society for Clinical Investigation.)
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Simultaneous injection of recombinant JE/MCP-1 and
recombinant TNF-a results in induction of the psoriasiform
skin inflammation in healthy skin of CD18hypo PL/J mice
MCP-1 is an important chemoattractant for macrophage
recruitment in various inflammations; an antagonist of MCP-1
has been reported to inhibit arthritis in the MRL-lpr mouse
model (Gong et al., 1997). Inhibition of MCP-1 and its
receptor (CCR2) pathway by another antagonist against CCR2
ameliorates development of diabetic nephropathy in animal
model (Kanamori et al., 2007). Interestingly, 17b-estradiol
(E2) was successfully used to inhibit MCP-1 production in
human keratinocytes derived from psoriatic skin in vitro
(Kanda and Watanabe, 2003). The beneficial effects of
antagonists of MCP-1 or its receptor CCR2 suggest that
blocking macrophage migration by inhibiting MCP-1/CCR2
interaction could have therapeutic application in inflamma-
tory diseases, such as psoriasis. However its causal contribu-
tion has not been elucidated in psoriasis.
Murine MCP-1 (CCL-2), originally termed JE, is considered
to be the equivalent of human MCP-1, even though it has an
extra 49-amino-acid fragment at the C-terminus. Murine
MCP-1 is a 125-amino-acid (25–30 kDa) member of the C–C
subfamily of chemokines (Ernst et al., 1994). It is produced by
immune and non-immune cells in response to various stimuli,
including TNF-a, IL-1b, IL-4, viruses, and endotoxins. MCP-1
has been shown to have chemoattractant properties for
monocytes, memory T-cells, natural killer cells, mast cells,
and basophils (Carroll et al., 1995; Tuaillon et al., 2002).
MCP-1 is postulated to be involved in several diseases,
including arteriosclerosis, rheumatoid arthritis, and multiple
sclerosis (Yla-Herttuala et al., 1991; Huang et al., 2001).
These data indicate that MCP-1 is a major proinflammatory
cytokine. Studies using a murine model of Schistosoma
mansoni-induced pulmonary granuloma, a murine model of
acute septic peritonitis, and studies of murine models of
lipopolysaccharide-induced sepsis indicate that MCP-1 can
also act as an anti-inflammatory cytokine (Chensue et al.,
1996; Matsukawa et al., 1999; Bone-Larson et al., 2000).
Another role for MCP-1 has been described in the develop-
ment of Th1 and Th2 (Matsukawa et al., 2000).
MCP-1-deficient mice (MCP-1/) have been generated
(Lu et al., 1998). They develop normally and have
normal hematological profiles, including normal number of
macrophages. Data show that despite expression of other
chemokines in these mice, MCP-1 is essential for monocyte
recruitment (Lu et al., 1998). In addition, a role for MCP-1 in
arteriosclerosis and experimental autoimmune encephalo-
myelitis has been demonstrated in MCP-1/ mice. MCP-1/
mice fed a high-cholesterol diet have less lipid deposition
throughout the aorta than do wt mice (Lu et al., 1998; Aiello
et al., 1999; Gosling et al., 1999). MCP-1 plays an important
role in the initiation of monocyte accumulation and lipid
deposition in atherosclerosis. Similarly, MCP-1/ mice
appear to be markedly resistant to experimental autoimmune
encephalomyelitis after active immunization, with drastically
impaired recruitment of macrophages to the CNS (Huang
et al., 2001). MCP-1 is necessary for Th1 immune responses
during experimental autoimmune encephalomyelitis, and
macrophage recruitment to the inflamed CNS is essential for
primed T-cells to execute a Th1-effector program in experi-
mental autoimmune encephalomyelitis.
Monocytes form a significant component of the inflam-
matory reaction occurring in the skin involved in atopic
dermatitis and psoriasis, and MCP-1 and CCR2 interaction is
likely of importance for the monocyte/macrophage trafficking
of inflammatory skin disorders (Vestergaard et al., 2004).
Previous studies demonstrated that the strongest MCP-1
signal in psoriatic lesions is found above the dermal–epider-
mal junction, and this may explain the characteristic sub-
basal distribution of dermal macrophages, suggesting that
MCP-1 is important in regulating the interaction between
proliferating keratinocytes and dermal macrophages in
psoriasis pathogenesis (Gillitzer et al., 1993).
To study whether the synergistic action of a factor
recruiting macrophages and a macrophages-activating proin-
flammatory cytokine may result in induction of the psoriasi-
form skin inflammation, recombinant JE/MCP-1 and
recombinant TNF-a were simultaneously injected. Indeed, 4
days after combined administration of recombinant JE/MCP-1
and recombinant TNF-a in unaffected skin of CD18hypo PL/J
mice, skin lesions were induced around the injection sites,
which were identical to those seen in the spontaneously
occurring chronic psoriasiform skin inflammation in
CD18hypo PL/J mice. Interestingly, clinical manifestation of
the chronic psoriasiform skin inflammation was reflected
histologically and by immunostaining showing an accumula-
tion and activation of macrophages. However, virtually no
recruitment of CD4þ T-cells was observed at day 10 after
treatment (Wang et al., 2006). These data may be in line with
previous data showing that CD4þ T-cells are able to activate
macrophages by release of Th1 cytokines such as IFN-g. In
fact, CD4þ T-cells of the CD18hypo mice have a 40-fold
increase in IFN-g release (Kess et al., 2003). However, once
macrophages are activated directly from proinflammatory
cytokines such as TNF-a, they have the capacity to induce the
psoriasiform inflammatory skin disease independent of
CD4þ T-cells. As human psoriasis is highly variable in its
clinical picture, our finding is of particular interest. It is
possible that psoriasis is also pathogenetically not a homo-
geneous entity, and while some cases may be caused by a
T-cell-dependent activation of macrophages, others may
occur via T-cell-independent mechanisms of macrophage
activation (Wrone-Smith and Nickoloff, 1996; Wang et al.,
2006). Only recently, the causal role of macrophages in other
T-cell-mediated disease like diabetes mellitus (Jun et al.,
1999), systemic lupus erythematosus (Varghese et al., 2007),
and rheumatoid arthritis (van Roon et al., 2005) was reported.
Pathogenic T-cells escaped from the control of dysfunctional
regulatory T-cells are involved in activation of macrophages
in CD18hypo PL/J mice
Even though there is still a debate in the field, most
researchers and clinicians regard psoriasis as a T-cell-
mediated inflammatory skin disease (Schon et al., 1997;
Nickoloff and Wrone-Smith, 1999; Boyman et al., 2004;
Schon and Boehncke, 2005; Sugiyama et al., 2005; Conrad
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et al., 2007). Dysfunctional CD4þCD25þ Treg-cells in
peripheral blood in association with accelerated proliferation
of CD4þCD25 responder T-cells may contribute to deve-
lopment of human psoriasis (Sugiyama et al., 2005). So far,
their causal role and interaction with other T-cell subtypes is
poorly understood in psoriasis.
We now have experimental evidence of the causal
contribution of CD18hypo Treg-cells in the development of
psoriasiform skin disease in the CD18hypo murine model of
psoriasis. Our data show that CD18hypo Treg-cells are
dysfunctional in suppressing pathogenic T-cell responses,
whereas CD18wt Treg-cells function normally. The reduced
CD18 expression on Treg-cells resulted in disruption of the
immunological synapse between DCs and Treg-cells, even-
tually impairing generation of functional antigen-specific
Treg-cells in CD18
hypo PL/J mice. Moreover, CD18hypo
Treg-cells have disrupted cell–cell contact with DCs, with
subsequently decreased expression of transforming growth
factor-b1. The reduced level of transforming growth factor-b1
is responsible for the decreased suppressor function of
Treg-cells, with enhanced generation of activated pathogenic
T-cells, which are causal for the onset and severity of
psoriasiform skin disease (data submitted for publication).
The role of CD18 in Treg-cell activation/education and
function in the control of autoimmunity is not fully under-
stood (Marski et al., 2005). Marski et al. injected CD18-
deficient T-cells into severe combined immunodeficient mice
and observed severe colitis. However, under lymphopenic
conditions, homeostatic expansion of pathogenic T-cells
may be responsible for the induction of the colitis; the role
of Treg-cells remains unclear in this model.
In contrast to the complete CD18 deficiency in CD18-null
mice, where neither Treg-cells nor responder T-cells can
migrate into the skin (Kess et al., 2003), T-cell emigration into
skin does occur in the CD18hypo PL/J mouse model, thus
allowing studies on Treg-cell/DC interaction in the lymph
node and the skin. Our major finding is that CD18wt
Treg-cells, when adoptively transferred into affected CD18
hypo
PL/J mice even at low numbers, led to resolution of the
psoriasiform skin phenotype. This clearly strengthens the
view that not only absent (Marski et al., 2005), but also
reduced CD18 expression, results in a severe defect in
regulatory function of Treg-cells in the CD18
hypo PL/J mice.
Reduced Treg-cell function in CD18
hypo PL/J mice is
consistent with previous results that IL-2- or IL-2R-deficient
mice are deficient in CD4þCD25þ suppressor T-cells in
secondary lymphoid organ (Furtado et al., 2002). Given the
known defect in the activation and IL-2 production of CD18/
T-cells (Marski et al., 2005), we suggest that low CD18
expression results in impaired immune synapse formation
between DCs and Treg-cells, with subsequently impaired T-cell
receptor activation, eventually leading to decreased prolifera-
tion and reduced suppressor function of Treg-cells. This view is
distinctly supported by the impaired cluster formation between
DCs and CD18hypo Treg-cells as compared with that between
DCs and CD18wt Treg-cells (data submitted for publication).
Disturbance in the immune synapse between DC–Treg-cells or
in the downstream signaling pathway have been reported for
other autoimmune diseases (van de Kerkhof and Weemaes,
1990; Gencik et al., 2000; Meller et al., 2001). It remains to be
further studied whether polymorphisms or mutations contri-
buting to immune synapse and/or T-cell receptor activation in
DC–Treg-cell contacts may be responsible for the observed lack
of Treg-cell-mediated suppression of autoimmune diseases.
Interestingly, aE (CD103)-deficient mice also develop the
cutaneous inflammatory phenotype (Schon et al., 2000).
aEb7-Integrin is normally expressed by CD4
þ and CD8þ
T-cells in mucosal and other epithelial compartments such as
skin or lung, and is thought to mediate intraepithelial
retention of T-cells (Sigmundsdottir et al., 2004). The
expression of the aEb7-integrin is a marker for a subset of
highly potent, functionally distinct Treg-cells specialized for
cross talk within epithelial environments (Lehmann et al.,
2002). Similar to the CD18hypo mouse model, the phenotype
of (CD103)-deficient mice may indicate that aEb7-integrin is
directly involved in the function or generation of Treg-cells as
loss of its expression results in such a severe inflammatory
phenotype (Schon et al., 2000; Lehmann et al., 2002).
With the identification of macrophages to play a critical
role in the psoriasiform skin disease, a new model for
pathogenesis events in psoriasis is emerging (Figure 6). In this
model, dermal DC activation is the key event for the
development of psoriasis in predisposed individuals. Many
stimuli can lead to activation of dermal DCs, including injury
and infection with organisms that trigger DC pathogen–
recognition receptors. Once dermal DCs are activated,
they trigger the activation of autoreactive T-cells, leading to
their proliferation (reviewed by Clark and Kupper, 2006).
In case Treg-cells are dysfunctional, as shown in CD18
hypo
PL/J mouse model of psoriasis and in human psoriasis
(Sugiyama et al., 2005), we suggest a sequence of pathogenic
events in the development of the psoriasiform skin disease,
where a decrease in CD18 expression impairs DC-Treg-cell
interaction, with diminished suppressive function and sub-
sequent hyperactivation of pathogenic T-cells (Bullard et al.,
1996; Kess et al., 2003). These activated pathogenic T-cells,
together with activated dermal DCs, secrete inflammatory
cytokines that induce production of MCP-1 and other
chemotactic factors by keratinocytes, leading to an influx
of macrophages and DCs (reviewed by Clark and Kupper,
2006). The recruitment and activation of macrophages
subsequently over-produce the proinflammatory cytokine
TNF-a, leading to overall amplification and maintenance of
the inflammatory process and thus the psoriasiform skin
disease (Figure 6).
The polygenic CD18hypo PL/J murine psoriasis model
described here may help to define modifier genes, which in
addition to the CD18hypo mutation, contribute to the psorias-
iform phenotype. The independent genetic approach may help
to define novel gene/genes interacting with the function of
b2-integrins, genes, which may also provide important insight
into the pathogenetic sequence of human psoriasis.
PERSPECTIVES AND CONCLUSION
Several other T-cell-mediated mouse models of psoriasis have
a phenotype similar to psoriasis. Xenograft models, in which
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symptomless (PN) skin derived from patients with psoriasis
are engrafted onto severe combined immunodeficient mice
or AGR129 mice, are the only models that closely reflect the
complete genetic, immunological, and phenotypic changes
of human psoriasis (Wrone-Smith and Nickoloff, 1996; Schon
et al., 1997; Nickoloff and Wrone-Smith, 1999; Boyman
et al., 2004; Conrad et al., 2007; Gudjonsson et al., 2007).
These models have conclusively shown that psoriasis is a
T-cell-mediated disease. The psoriatic skin lesions described
in xenograft models demonstrate many features resembling the
CD18hypo PL/J mouse model of psoriasis, including thicken-
ing and hyperkeratosis of the epidermal layer, infiltration of
immunocytes (CD4þ T-cells, CD8þ T-cells, dermal DCs,
macrophages, mast cells), and proliferation of blood vessels.
In these xenograft models, a number of cytokines charac-
teristic of psoriasis were upregulated, including IFN-g,
TNF-a, IL-1, IL-6, and IL-12. Such cytokines were markedly
increased in the CD18hypo PL/J mouse model of psoriasis.
Notably, similar to the CD18hypo PL/J mouse model, neutrali-
zation of TNF-a using an mAb against TNF-a (infliximab) or a
soluble TNF-receptor fusion protein (etanercept) significantly
decreased the psoriatic phenotype in xenograft models
(Boyman et al., 2004; Gordon et al., 2005). However, studies
on the role of activated macrophages in these animals are still
lacking, and whether activation of macrophages is involved
in the pathogenesis of psoriatic inflammation in xenograft
models, remains to be clarified.
In conclusion, the herein summarized data from the
CD18hypo PL/J psoriasis mouse model in the context of the
current literature demonstrates that the psoriasiform inflam-
matory skin disorder critically depends on an appropriate
activation of macrophages, with sufficient release of TNF-a.
In this model, T-cells are required for macrophage recruit-
ment and activation, as previously shown by the fact that
depletion of CD4þ T-cells from these mice induced
complete resolution of skin disease (Kess et al., 2003; Clark
and Kupper, 2006; Wang et al., 2006). Our recent data shed
light on a mechanistic basis of the involvement of a shifted
immune balance between regulatory T-cells and autoreactive
T-cells. Dysfunctional Treg-cells caused by reduced expres-
sion of CD18 in CD18hypo PL/J mice are responsible for
unrestrained activation of pathogenic T-cells. Based on our
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T-cells, which recruit and activate macrophages within the dermis by production of IFN-g or others. Activated macrophages with TNF-a release induce activation
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of monocytes from the blood, which undergo differentiation into macrophages and myeloid dendritic cells to maintain and amplify the inflammation and stimulate
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findings (Wang et al., 2006), an emerging model of psoriasis
pathogenesis in humans suggests that dermal macrophages,
once activated by T-cell cytokines, then produce large
amounts of TNF-a, leading to skin changes (Clark and
Kupper, 2006).
These features shared with human psoriasis make this
model a valuable tool for future investigations into the
pathogenesis of chronic inflammatory skin diseases such as
human psoriasis—including their polygenic base—and for
future preclinical studies.
The CD18hypo PL/J mouse model, thus, allowed us to
provide evidence for the important role of macrophages in
the pathogenesis of a T-cell-mediated animal model for
psoriasis, as being also suggested for other autoimmune
diseases (Table 1). The causal role of macrophages in a
variety of inflammatory diseases just starts to emerge.
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